Nitriles

"Nitriles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE.

Descriptor ID	D009570
MeSH Number(s)	D02.626
Concept/Terms	Nitriles Nitriles

Below are MeSH descriptors whose meaning is more general than "Nitriles".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Nitriles [D02.626]

Below are MeSH descriptors whose meaning is more specific than "Nitriles".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Nitriles" by people in this website by year, and whether "Nitriles" was a major or minor topic of these publications.

Bar chart showing 41 publications over 22 distinct years, with a maximum of 4 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1997	0	1	1
2002	1	0	1
2004	1	0	1
2005	1	1	2
2006	0	1	1
2007	0	1	1
2008	2	2	4
2009	0	2	2
2010	2	1	3
2011	0	2	2
2012	1	1	2
2013	1	2	3
2014	1	2	3
2015	0	2	2
2016	0	3	3
2018	0	1	1
2019	0	1	1
2020	0	3	3
2021	1	1	2
2022	1	0	1
2023	0	1	1

Below are the most recent publications written about "Nitriles" by people in Profiles.

Flynn JM, Huang QYJ, Zvornicanin SN, Schneider-Nachum G, Shaqra AM, Yilmaz NK, Moquin SA, Dovala D, Schiffer CA, Bolon DNA. Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease. ACS Infect Dis. 2023 Jul 14; 9(7):1372-1386.

View in: PubMed
Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022 10 20; 387(16):1445-1455.

View in: PubMed
Rizzo A, Oderda M, Mollica V, Merler S, Morelli F, Fragomeno B, Taveri E, Sorgentoni G, Santoni M, Massari F. A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents. Anticancer Drugs. 2022 01 01; 33(1):e43-e51.

View in: PubMed
Nigro MC, Mollica V, Marchetti A, Cheng M, Rosellini M, Montironi R, Cheng L, Massari F. Current androgen receptor antagonists under investigation for resistant prostate cancer. Expert Rev Anticancer Ther. 2022 Feb; 22(2):191-202.

View in: PubMed
O'Hara BA, Gee GV, Haley SA, Morris-Love J, Nyblade C, Nieves C, Hanson BA, Dang X, Turner TJ, Chavin JM, Lublin A, Koralnik IJ, Atwood WJ. Teriflunomide Inhibits JCPyV Infection and Spread in Glial Cells and Choroid Plexus Epithelial Cells. Int J Mol Sci. 2021 Sep 10; 22(18).

View in: PubMed
Hamzavi I, Rosmarin D, Harris JE, Pandya AG, Lebwohl M, Gottlieb AB, Butler K, Kuo FI, Sun K, Grimes P. Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial. J Am Acad Dermatol. 2022 06; 86(6):1398-1401.

View in: PubMed
Mozo Y, Bueno D, Sisinni L, Fern?ndez-Arroyo A, Rosich B, Mart?nez AP, Ben?tez-Carabante MI, Alonso L, Ur?a ML, Heredia CD, Mestre-Duran C, Pascual CFB, Torres J, Losantos I, Escudero A, Ruz-Caracuel B. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity. Pediatr Hematol Oncol. 2021 May; 38(4):331-345.

View in: PubMed
Kohrt SE, Awadallah WN, Phillips RA, Case TC, Jin R, Nanda JS, Yu X, Clark PE, Yi Y, Matusik RJ, Anderson PD, Grabowska MM. Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells In Vitro. Mol Cancer Ther. 2021 02; 20(2):398-409.

View in: PubMed
Rosmarin D, Butler K, Kuo F, Harris JE. Ruxolitinib cream for the treatment of vitiligo - Authors' reply. Lancet. 2020 11 28; 396(10264):1736.

View in: PubMed
Rosmarin D, Pandya AG, Lebwohl M, Grimes P, Hamzavi I, Gottlieb AB, Butler K, Kuo F, Sun K, Ji T, Howell MD, Harris JE. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020 07 11; 396(10244):110-120.

View in: PubMed

People

Explore

Similar Concepts

Top Journals